Bimekizumab offers fresh option for patients with chronic conditions
Bimekizumab offers fresh option for patients with chronic conditions
hVIVO celebrates landmark deal highlighting its role in advancing influenza therapy
Collaboration aims to streamline manufacturing linking nhs early-phase expertise
Foundation’s test to be used in Oxford-led blood biomarker trial
First long-acting therapy with three-monthly dosing to target root cause of cardiac disease
First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients
Five-year deal aims to support UK biomedical talent and drive collaboration across sectors
Positive topline results highlight potential new option for secondary stroke prevention
Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases
New patent strengthens IP position for treatment of influenza side effects
Protara’s phase 2 STARBORN-1 study reports high response rates and no serious adverse events
New authorisation marks major milestone in earlier treatment of skin cancer
Munich-based start-up backed by Frontline Ventures and Y Combinator eyes global expansion
Six new Grand Challenges aim to tackle drug resistance and accelerate antibiotic discovery
New ONE BioHub facility expands clinical trial access and strengthens Scotland’s brain health innovation